v3.23.3
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows From Operating Activities:    
Net loss $ (37,198) $ (27,897)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 20,038 16,631
Amortization of debt discount 1,928 1,930
Non-cash operating lease expense 3,403 2,688
Unrealized (gain) loss on investments in equity securities 2,255 12,436
Realized loss on available-for-sale investments 62 113
Stock-based compensation expense 16,960 14,749
Loss on disposal of property and equipment 277 574
Gain on extinguishment of debt, net (5,679)  
Gain on insurance settlement (2,642) (4,815)
Change in credit losses (135) 13
Excess and obsolete inventory   546
Insurance proceeds for operations 1,212 6,429
Change in contingent consideration (205) 145
Changes in operating assets and liabilities:    
Accounts receivable 1,088 (8,307)
Inventories (1,572) (11,179)
Prepaid expenses and other current assets (2,298) (1,419)
Deposits (652) 9
Operating lease liabilities (3,009) (2,372)
Accounts payable and other accrued expenses (36) (3,172)
Accrued compensation and related expenses 2,013 (1,218)
Deferred revenue 1,141 (420)
Net deferred tax liability (190) (969)
Net cash used in operating activities (3,239) (5,505)
Cash Flows From Investing Activities:    
Purchases of property and equipment (27,212) (14,250)
Insurance proceeds for loss of fixed assets 976 3,000
Software development costs (4,830) (965)
Purchases of short-term investments   (155,353)
Acquisitions   (6,554)
Sales/maturities of short-term investments 82,487 107,835
Patent and trademark costs (616) (518)
Net cash provided by (used in) investing activities 50,805 (66,805)
Cash Flows From Financing Activities:    
Proceeds from exercise of stock options 1,480 1,596
Repurchase of common stock   (33,349)
Cash paid for repurchase of 2026 Senior Notes (25,003)  
Repayment of notes payable (26) (2,069)
Repayment of finance lease liabilities (123) (46)
Net cash used in financing activities (23,672) (33,868)
Effect of exchange rates on cash and cash equivalents (1,016) (2,199)
Net change in cash and cash equivalents 22,878 (108,377)
Cash and cash equivalents - beginning of period 36,595 139,101
Cash and cash equivalents - end of period 59,473 30,724
Supplemental Disclosure of Cash Flow Information:    
Cash paid for interest 1,792 1,904
Cash paid for income taxes 951 1,276
Supplemental Disclosure of Non-Cash Financing Activities:    
Operating lease right-of-use assets and operating lease liabilities 9,581 5,084
Net unrealized gain (loss) on available-for-sale debt securities 3,076 (25,912)
Reclassification of realized gain (loss) on available-for-sale debt securities to earnings 1,389 (46)
Paid-in-kind preferred stock dividend, including beneficial conversion feature 6,000 6,000
Fixed assets included in accounts payable and accrued liabilities $ 572 481
Receivable included in prepaid expenses and other current assets   3,033
Common stock issued for Cell&Co acquistion   $ 479

Source